Tiffany Wedekind, a resident of Columbus, Ohio, was not expected to reach this age, yet at 48 she is defying medical predictions. She lives with Hutchinson-Gilford progeria (HGPS), a rare and fatal genetic disorder that causes accelerated aging—but continues to live a full life. Her story recently came to public attention in the United States after she appeared on the television program One Day In My Body, which focuses on people dealing with extraordinary medical conditions, drawing renewed attention to a rare disease that in most cases does not allow patients to reach adulthood.
The changes in her body began appearing around age 12. Wedekind describes living with the condition as living “in the body of a woman over 80.”
HGPS is not only expressed in an older appearance. Symptoms include stunted growth, difficulty gaining weight, hair loss, thin and wrinkled skin —along with a range of additional health complications. On average, life expectancy for those with the disease is only 7 to 13 years. Wedekind, however, is breaking all statistics: approaching 50, she is considered one of the oldest known survivors with the condition—a rare achievement reached by very few.
In her case, the data highlights just how unusual her body is: she weighs about 26 kilograms and is approximately 132 centimeters tall. She was not joking when she described herself as living “in the body of someone over 80.” According to her, the first changes began around age 12. “I started noticing my fingers were different,” she said. “My nails weren’t like the other girls’. Everyone else was painting their nails and doing things like that—and I couldn’t, because I simply didn’t have nails.”
But behind her personal story lies an unusual family history. Unlike most cases of HGPS, which occur randomly, Wedekind’s case is exceptionally rare and genetic. Her mother and brother also had the disease. Her brother, Chad, died at age 39, and the family has donated DNA samples to research in hopes of supporting future treatments. Still, those who knew Wedekind, describe her childhood far from the typical image of a patient. “Tiffany wasn’t sick in the usual sense as a child,” her brother Todd said. “She did everything everyone else did. She was just smaller.”
Her own memories also paint a different picture. She recalls being part of a cheerleading team in middle school and appearing in a photo doing the splits in uniform. “I was happy,” she said. “I just thought about the pom-poms and waving them in the air.” Her friend Judy added that in high school she served as the team mascot: “Because she was so small, people would just lift her and carry her on their shoulders.” Another close friend, Jamie, described her as “an amazing, inspiring, and strong woman,” saying that knowing her is a privilege.
But despite the visible differences from a young age, Wedekind says they never defined her identity. “I knew I was different since I was little,” she admits, “but I didn’t know why, and I didn’t think much about it. I was too busy living my life.” Even today, she refuses to be defined solely by her medical condition. Alongside living with the disease, she runs an independent studio where she creates jewelry and candles, and works to raise awareness of the condition. She maintains an active lifestyle, including yoga and a carefully managed diet, and continues to emphasize one clear message: the disease may define the body, but not the life.
Behind Wedekind’s extraordinary story lies a complex disease that begins at the molecular level and affects nearly every system in the body. To better understand it, we spoke with Professor Lina Basel-Salmon. “HGPS is a very rare genetic disease, occurring in about 1 in 8 to 20 million people—different sources report slightly different numbers,” she said. “About 400 people worldwide are known to have it, and that is already based on older data. The disease causes accelerated aging at about ten times the normal rate.”
According to Prof. Basel-Salmon, the disease is caused by a small genetic mutation that disrupts normal cellular function. “It is caused by a change in a gene called LMNA,” she explained. “A small error in the genetic sequence produces a shortened protein called progerin. This protein is missing several amino acids—its building blocks. The altered protein sticks to the cell nucleus, interferes with cell division, and causes progressive damage. That is why the body shows signs of accelerated aging.”
The implications of this genetic change quickly become visible in early childhood. “Symptoms usually begin within the first year of life,” she confirmed. “The most noticeable are growth delays in height and weight. Later, classic signs appear—an enlarged head compared to the face and body, loss of subcutaneous fat, sparse hair, weak nails, thin skin, and dental problems. The voice may be high-pitched. But the main medical issue is cardiovascular disease. These patients can suffer strokes or heart attacks at a very young age, which is why life expectancy is short. Most die by around age 20, so Wedekind’s story reflects someone with unusually long survival.”
Prof. Basel-Salmon added that the disease cannot be predicted through routine genetic screening. “We cannot detect it in advance through standard screening because the mutation usually occurs in the egg or sperm, and the parents appear healthy. Even if we test their blood with the most advanced screening, we will not find it. We can only diagnose it before birth through amniocentesis and full DNA sequencing of the fetus.”
Once the disease develops, diagnosis is often clinical. “Patients with HGPS look very similar to each other—they appear almost like siblings,” she said. “We then confirm the diagnosis with genetic testing, which usually finds a recurring mutation in the LMNA gene. In about 10% of cases, there is another mutation in the same gene, so diagnosis is relatively straightforward.”
Treatment options remain limited. “There is a drug called lonafarnib, but it is not sufficiently effective. It can slightly extend life expectancy, and we can offer it to patients, but it is currently the only available treatment. Supportive care such as aspirin to prevent strokes, physical therapy, and close cardiology follow-up are also used—but none of these cure the disease,” she said.
Even future technologies face challenges. “Gene editing technologies are better suited to diseases affecting a single tissue. In HGPS, the problem exists in many tissues across the body once the child is born, so it is very difficult to deliver treatment to every cell,” she explained. “It is unlikely we will see a dramatic solution in the coming years. We can always hope for unexpected breakthroughs, but it remains complex. It is far better to prevent the disease through genetic diagnosis during pregnancy.”